Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma

Gross L, Mutisheva I, Hillen H, Robatel S, Wartenberg M, Ma F, Bäriswyl L, Lee DJ, Modlin RL, Z'graggen K, Schenk M. TREM-1 as a[...]

New-Onset Perianal Eroded Lesion in a Pediatric Patient

Yan MJ, Galamgam J, Shen A, Mo J, Hogeling M. New-Onset Perianal Eroded Lesion in a Pediatric Patient. Pediatr Dermatol. 2025 Sep 8. doi: 10.1111/pde.70037.[...]

Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy

Burshtein J, Bunick CG, Vleugels RA, Armstrong AW, Golant AK, Schlesinger T, Strober BE, Song EJ, Gold LS, Lebwohl M. Systemic Corticosteroid Use in Atopic[...]